Galbraith Kenneth
Chair & CEO
Galbraith Kenneth has filed 3 SEC Form 4 filings (8 transaction rows) across 1 company, with disclosures dating back to 2025. 3 of those filings fall inside the rolling window. Most recent filing: Jan 12, 2026.
On the most recent filing, Galbraith Kenneth is listed as Chair & CEO at Zymeworks Inc. Inside the rolling window, Galbraith Kenneth reported no open-market purchases and 3 open-market sales totaling $3.3M in ZYME. The largest disclosed transaction in the window is a sale of 54,343 ZYME shares on Jan 5, 2026, worth $1.4M.
Companies traded
Other insiders at ZYME
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$3.3M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Galbraith Kenneth made?
Galbraith Kenneth has filed 3 SEC Form 4 filings (8 transaction rows) across 1 company since 2025.
Which companies does Galbraith Kenneth trade?
Galbraith Kenneth has filed SEC Form 4 disclosures for 1 company, including ZYME.
When was Galbraith Kenneth's most recent SEC Form 4 filing?
Galbraith Kenneth's most recent SEC Form 4 filing on Tracefour is dated Jan 12, 2026.
What is Galbraith Kenneth's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Galbraith Kenneth is listed as Chair & CEO.
What is Galbraith Kenneth's total buy and sell value in the current window?
Inside the rolling retention window, Galbraith Kenneth bought $0 and sold $3.3M based on SEC Form 4 filings.
What was Galbraith Kenneth's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 54,343 ZYME shares on 2026-01-05, worth $1.4M, per SEC Form 4 filings.